Adjuvant dose-intense chemotherapy with peripheral blood stem cell support in stage II-III breast cancer with five to nine involved axillary lymph nodes

Lee Schwartzberg, Robert Birch, Kurt W. Tauer, Richard Leff, F. Anthony Greco, John Hainsworth, Eric Raefsky, Barbara McAneny, Zebulon Weaver, John West, C. Dean Buckner, Charles H. Weaver

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The purpose of this study is to determine outcomes for patients with high-risk nonmetastatic breast cancer undergoing high-dose chemotherapy with peripheral blood stem cell support. Forty-three patients with stage II-III disease, five to nine positive axillary lymph nodes, and a median age of 44 years (range, 27-60 years) were enrolled in a study that included: 1) standard dose doxorubicin, 5-fluorouracil, and methotrexate adjuvant therapy; 2) cyclophosphamide, etoposide, filgrastim, and peripheral blood stem cell harvest; and 3) high-dose cyclophosphamide, thiotepa, and carboplatin (CTCb) followed by peripheral blood stem cell infusion. All 43 patients received doxorubicin, 5-fluorouracil, and methotrexate, 42 (98%) received etoposide, and 41 (95%) received CTCb. Thirty-two patients (74%) are alive, 28 (65%) without relapse at a median of 55 months (range, 41-87 months). Two died (5%) of treatment-related causes, (subclavian catheter complication after etoposide and late radiation pneumonitis), and nine other deaths (21%) were associated with recurrent breast cancer. The probabilities of overall and event-free survival at 4 years were 0.77 and 0.67, respectively, compared with 0.82 and 0.69, respectively, for 72 similar patients with 10 or more positive axillary nodes receiving the same sequence of therapy. Thus, patients with five to nine positive axillary lymph nodes have a similar risk of failure after high-dose chemotherapy and peripheral blood stem cell support as patients with 10 or more positive axillary lymph nodes.

Original languageEnglish (US)
Pages (from-to)136-142
Number of pages7
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume22
Issue number2
DOIs
StatePublished - Apr 1 1999
Externally publishedYes

Fingerprint

Lymph Nodes
Breast Neoplasms
Drug Therapy
Etoposide
Cyclophosphamide
Thiotepa
Carboplatin
Methotrexate
Fluorouracil
Doxorubicin
Radiation Pneumonitis
Peripheral Blood Stem Cells
Disease-Free Survival
Therapeutics
Catheters
Recurrence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Adjuvant dose-intense chemotherapy with peripheral blood stem cell support in stage II-III breast cancer with five to nine involved axillary lymph nodes. / Schwartzberg, Lee; Birch, Robert; Tauer, Kurt W.; Leff, Richard; Greco, F. Anthony; Hainsworth, John; Raefsky, Eric; McAneny, Barbara; Weaver, Zebulon; West, John; Buckner, C. Dean; Weaver, Charles H.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 22, No. 2, 01.04.1999, p. 136-142.

Research output: Contribution to journalArticle

Schwartzberg, Lee ; Birch, Robert ; Tauer, Kurt W. ; Leff, Richard ; Greco, F. Anthony ; Hainsworth, John ; Raefsky, Eric ; McAneny, Barbara ; Weaver, Zebulon ; West, John ; Buckner, C. Dean ; Weaver, Charles H. / Adjuvant dose-intense chemotherapy with peripheral blood stem cell support in stage II-III breast cancer with five to nine involved axillary lymph nodes. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1999 ; Vol. 22, No. 2. pp. 136-142.
@article{c32d9888864247f3b78ebd4c08f19b1f,
title = "Adjuvant dose-intense chemotherapy with peripheral blood stem cell support in stage II-III breast cancer with five to nine involved axillary lymph nodes",
abstract = "The purpose of this study is to determine outcomes for patients with high-risk nonmetastatic breast cancer undergoing high-dose chemotherapy with peripheral blood stem cell support. Forty-three patients with stage II-III disease, five to nine positive axillary lymph nodes, and a median age of 44 years (range, 27-60 years) were enrolled in a study that included: 1) standard dose doxorubicin, 5-fluorouracil, and methotrexate adjuvant therapy; 2) cyclophosphamide, etoposide, filgrastim, and peripheral blood stem cell harvest; and 3) high-dose cyclophosphamide, thiotepa, and carboplatin (CTCb) followed by peripheral blood stem cell infusion. All 43 patients received doxorubicin, 5-fluorouracil, and methotrexate, 42 (98{\%}) received etoposide, and 41 (95{\%}) received CTCb. Thirty-two patients (74{\%}) are alive, 28 (65{\%}) without relapse at a median of 55 months (range, 41-87 months). Two died (5{\%}) of treatment-related causes, (subclavian catheter complication after etoposide and late radiation pneumonitis), and nine other deaths (21{\%}) were associated with recurrent breast cancer. The probabilities of overall and event-free survival at 4 years were 0.77 and 0.67, respectively, compared with 0.82 and 0.69, respectively, for 72 similar patients with 10 or more positive axillary nodes receiving the same sequence of therapy. Thus, patients with five to nine positive axillary lymph nodes have a similar risk of failure after high-dose chemotherapy and peripheral blood stem cell support as patients with 10 or more positive axillary lymph nodes.",
author = "Lee Schwartzberg and Robert Birch and Tauer, {Kurt W.} and Richard Leff and Greco, {F. Anthony} and John Hainsworth and Eric Raefsky and Barbara McAneny and Zebulon Weaver and John West and Buckner, {C. Dean} and Weaver, {Charles H.}",
year = "1999",
month = "4",
day = "1",
doi = "10.1097/00000421-199904000-00006",
language = "English (US)",
volume = "22",
pages = "136--142",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Adjuvant dose-intense chemotherapy with peripheral blood stem cell support in stage II-III breast cancer with five to nine involved axillary lymph nodes

AU - Schwartzberg, Lee

AU - Birch, Robert

AU - Tauer, Kurt W.

AU - Leff, Richard

AU - Greco, F. Anthony

AU - Hainsworth, John

AU - Raefsky, Eric

AU - McAneny, Barbara

AU - Weaver, Zebulon

AU - West, John

AU - Buckner, C. Dean

AU - Weaver, Charles H.

PY - 1999/4/1

Y1 - 1999/4/1

N2 - The purpose of this study is to determine outcomes for patients with high-risk nonmetastatic breast cancer undergoing high-dose chemotherapy with peripheral blood stem cell support. Forty-three patients with stage II-III disease, five to nine positive axillary lymph nodes, and a median age of 44 years (range, 27-60 years) were enrolled in a study that included: 1) standard dose doxorubicin, 5-fluorouracil, and methotrexate adjuvant therapy; 2) cyclophosphamide, etoposide, filgrastim, and peripheral blood stem cell harvest; and 3) high-dose cyclophosphamide, thiotepa, and carboplatin (CTCb) followed by peripheral blood stem cell infusion. All 43 patients received doxorubicin, 5-fluorouracil, and methotrexate, 42 (98%) received etoposide, and 41 (95%) received CTCb. Thirty-two patients (74%) are alive, 28 (65%) without relapse at a median of 55 months (range, 41-87 months). Two died (5%) of treatment-related causes, (subclavian catheter complication after etoposide and late radiation pneumonitis), and nine other deaths (21%) were associated with recurrent breast cancer. The probabilities of overall and event-free survival at 4 years were 0.77 and 0.67, respectively, compared with 0.82 and 0.69, respectively, for 72 similar patients with 10 or more positive axillary nodes receiving the same sequence of therapy. Thus, patients with five to nine positive axillary lymph nodes have a similar risk of failure after high-dose chemotherapy and peripheral blood stem cell support as patients with 10 or more positive axillary lymph nodes.

AB - The purpose of this study is to determine outcomes for patients with high-risk nonmetastatic breast cancer undergoing high-dose chemotherapy with peripheral blood stem cell support. Forty-three patients with stage II-III disease, five to nine positive axillary lymph nodes, and a median age of 44 years (range, 27-60 years) were enrolled in a study that included: 1) standard dose doxorubicin, 5-fluorouracil, and methotrexate adjuvant therapy; 2) cyclophosphamide, etoposide, filgrastim, and peripheral blood stem cell harvest; and 3) high-dose cyclophosphamide, thiotepa, and carboplatin (CTCb) followed by peripheral blood stem cell infusion. All 43 patients received doxorubicin, 5-fluorouracil, and methotrexate, 42 (98%) received etoposide, and 41 (95%) received CTCb. Thirty-two patients (74%) are alive, 28 (65%) without relapse at a median of 55 months (range, 41-87 months). Two died (5%) of treatment-related causes, (subclavian catheter complication after etoposide and late radiation pneumonitis), and nine other deaths (21%) were associated with recurrent breast cancer. The probabilities of overall and event-free survival at 4 years were 0.77 and 0.67, respectively, compared with 0.82 and 0.69, respectively, for 72 similar patients with 10 or more positive axillary nodes receiving the same sequence of therapy. Thus, patients with five to nine positive axillary lymph nodes have a similar risk of failure after high-dose chemotherapy and peripheral blood stem cell support as patients with 10 or more positive axillary lymph nodes.

UR - http://www.scopus.com/inward/record.url?scp=17144465348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144465348&partnerID=8YFLogxK

U2 - 10.1097/00000421-199904000-00006

DO - 10.1097/00000421-199904000-00006

M3 - Article

VL - 22

SP - 136

EP - 142

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -